{"id":3770,"date":"2026-09-23T11:31:53","date_gmt":"2026-09-23T11:31:53","guid":{"rendered":"https:\/\/drsoniafawad.com\/?p=3770"},"modified":"2026-09-23T11:31:53","modified_gmt":"2026-09-23T11:31:53","slug":"marijuana-use-linked-to-symptom-control-in-ibd","status":"publish","type":"post","link":"https:\/\/drsoniafawad.com\/?p=3770","title":{"rendered":"Marijuana use linked to symptom control in IBD"},"content":{"rendered":"<p><br \/>\n<\/p>\n<div data-component=\"ArticleContent\">\n<div class=\"article__below-title\">\n<div class=\" article__posted-date\">\n<p>September 23, 2026<\/p>\n<p>3 min read<\/p>\n<\/p><\/div>\n<div class=\"mobile-trust-box\">\n<div class=\"row\">\n<div class=\"col-12 col-md-5 d-xl-none\">\n<div class=\"trust-box\">\n<div class=\"trust-box-logo d-none d-md-block\">\n            <img decoding=\"async\" src=\"https:\/\/www.healio.com\/~\/media\/h5\/feature\/news\/publogos\/hgld\/healio_gastro.svg?la=en&amp;h=40&amp;w=152&amp;hash=2C654A538F2E250F5183D42A89FE0EC0\" class=\"logo-img\" height=\"40\" alt=\"Healio Logo - Gastroenterology\" width=\"152\"\/>\n          <\/div>\n<\/p><\/div>\n<\/p><\/div>\n<div class=\"col-12 col-md-6 offset-md-1 offset-xl-0 col-xl-12\">\n<div class=\"email-alert-button-wrapper d-none\" data-component=\"EmailTopicAlert\" data-module=\"Subspecialty Email Topic Alerts Top\" data-manage-email-link=\"\/footer\/account-information\/my-account\/email-subscriptions-and-alerts#emailAlerts\">\n  <hidden data-setting-item=\"d265901d-6d37-49c7-a8f6-c7bf19a02509\"\/><br \/>\n  <hidden data-crm-source=\"Subspecialty Topic Alert\"\/><\/p>\n<div class=\"email-alert-button d-none\" data-topic-button=\"not-subscribed\">\n<p>&#13;<br \/>\n      <span data-module-track-action=\"Email Alerts TOP_Click_Healio News Article\" data-module-track-label=\"Email Alerts TOP_Healio News Article\">&#13;<br \/>\n        <i class=\"fas fa-plus-circle\"\/>&#13;<br \/>\n        Add topic to email alerts&#13;<br \/>\n      <\/span>&#13;\n    <\/p>\n<div class=\"email-alert-inner collapse u72666b614ef0406bbd8736de479e5a93\">\n<div class=\"email-alert-dialogue\">\n<p>&#13;<br \/>\n          Receive an email when new articles are posted on <span data-content=\"topic-title\"\/>&#13;\n        <\/p>\n<div class=\"d-none\" data-sign-up-type=\"unknown\">\n          Please provide your email address to receive an email when new articles are posted on <span data-content=\"topic-title\"\/>.<\/p><\/div>\n<\/p><\/div>\n<p>      <button type=\"button\" class=\"btn btn-primary\" data-loading-text=\"Loading &lt;i class=\" fa=\"\" fa-spinner=\"\" fa-spin=\"\">&#8220;&#13;<br \/>\n              data-action=&#8221;subscribe&#8221;&gt;&#13;<br \/>\n        Subscribe&#13;<br \/>\n      <\/button>\n    <\/div>\n<\/p><\/div>\n<div class=\"d-none\" data-topic-modal=\"failed\">    <strong>We were unable to process your request. Please try again later. If you continue to have this issue please contact <a href=\"https:\/\/www.healio.com\/news\/gastroenterology\/20260922\/mailto:customerservice@slackinc.com\">customerservice@slackinc.com<\/a>.<\/strong>  <\/p>\n<p><button data-dismiss=\"modal\" class=\"btn btn-primary btn-lg btn-block\">Back to Healio<\/button><\/p>\n<\/div>\n<\/div><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/div>\n<h2>Key takeaways:<\/h2>\n<ul>\n<li>Nearly 70% of survey respondents reported daily\/near daily marijuana use for symptom control.<\/li>\n<li>Use was tied to patient-reported relief of anxiety, joint pain and nausea\/vomiting, and better quality of life.<\/li>\n<\/ul>\n<p>Patients with inflammatory bowel disease who used marijuana reported symptom relief, improved daily functioning and reduced opioid analgesic use, survey results showed.<\/p>\n<p>      <a rel=\"noopener noreferrer\" href=\"https:\/\/www.healio.com\/news\/gastroenterology\/20250828\/notable-proportion-of-patients-with-ibd-rely-on-cannabis-or-cbd-oil-for-relief\" id=\"rId9\" target=\"_blank\">Prior research<\/a> indicates some patients with IBD use marijuana to manage disease symptoms or treatment-related adverse events.<\/p>\n<figure class=\"figure article__og-image\">&#13;\n    <picture>&#13;<source srcset=\"https:\/\/www.healio.comhttps:\/\/www.healio.comhttps:\/\/www.healio.com\/~\/media\/slack-news\/gastroenterology\/misc\/infographics\/2026\/0926\/hgi0826daneshmand_graphic_01.webp?w=476\" media=\"(max-width: 768px)\">&#13;<source srcset=\"https:\/\/www.healio.com\/~\/media\/slack-news\/gastroenterology\/misc\/infographics\/2026\/0926\/hgi0826daneshmand_graphic_01.webp?w=800\" media=\"(max-width: 992px)\">&#13;<source srcset=\"https:\/\/www.healio.com\/~\/media\/slack-news\/gastroenterology\/misc\/infographics\/2026\/0926\/hgi0826daneshmand_graphic_01.webp?w=595\" media=\"(max-width: 1200px)\">&#13;<source srcset=\"https:\/\/www.healio.comhttps:\/\/www.healio.comhttps:\/\/www.healio.com\/~\/media\/slack-news\/gastroenterology\/misc\/infographics\/2026\/0926\/hgi0826daneshmand_graphic_01.webp?w=476\" media=\"(min-width: 1200px)\">&#13;<source srcset=\"https:\/\/www.healio.comhttps:\/\/www.healio.comhttps:\/\/www.healio.com\/~\/media\/slack-news\/gastroenterology\/misc\/infographics\/2026\/0926\/hgi0826daneshmand_graphic_01.webp?w=476\">&#13;<br \/>\n&#13;<br \/>\n      <img decoding=\"async\" src=\"https:\/\/www.healio.com\/~\/media\/slack-news\/gastroenterology\/misc\/infographics\/2026\/0926\/hgi0826daneshmand_graphic_01.jpg?w=800\" alt=\"The most common symptoms patients with IBD reported using marijuana for IG\" class=\"figure-img img-fluid\" width=\"800\"\/>&#13;<br \/>\n    <\/source><\/source><\/source><\/source><\/source><\/picture>&#13;<figcaption class=\"figure-caption\">&#13;<br \/>\n      Data derived from Daneshmand A, et al. <i>Med Cannabis Cannabinoids<\/i>. 2026;doi:10.1159\/000553354.&#13;<br \/>\n    <\/figcaption>&#13;<br \/>\n  <\/figure>\n<div class=\"mug left\"><img decoding=\"async\" alt=\"Naueen A. Chaudhry, MD\" style=\" height:106px; width:80px\" src=\"https:\/\/www.healio.com\/~\/media\/slack-news\/hemonc\/mugs\/c\/chaudhry_naueen_2026_.jpg\"\/><\/p>\n<p><strong><b>Naueen A. Chaud<\/b><b>h<\/b><b>ry<\/b><\/strong><\/p>\n<\/div>\n<p>\u201cMarijuana use is prevalent for symptom control among patients with IBD and is rising with legalization; however, it is often not discussed in clinic visits,\u201d <b>Naueen A. Chaud<\/b><b>h<\/b><b>ry<\/b><b>, MD, <\/b>assistant professor of gastroenterology at University of Florida, told Healio. \u201cPhysicians managing IBD do not have extensive data on the patient experience and symptom response to marijuana use.\u201d<\/p>\n<h2>IBD and marijuana use <\/h2>\n<p>The number of U.S. states in which marijuana use currently is legal \u2014 38 states for medicinal use and 24 for recreational \u2014 continues to expand. Medical marijuana use is legal in Florida, where this study took place, and Crohn\u2019s disease is an approved indication.<\/p>\n<p>Chaudhry and colleagues administered a 39-question survey to 108 patients at the University of Florida\u2019s IBD clinic who were diagnosed with CD or ulcerative colitis (51.9% women; 50% aged 26 to 45 years; 79.6% CD) and reported using marijuana. <\/p>\n<p>\u201cOur goal was to gain a better understanding of our patients, including their patterns of use, experiences and perceptions of marijuana use in the context of disease-related symptoms,\u201d Chaudhry said.<\/p>\n<p>The majority (82.4%) of patients were on pharmacotherapy for IBD, with more than half (56.5%) reporting current biologic use.<\/p>\n<p>Participants most often used marijuana for anxiety (60.2%), joint pain (54.6%), and nausea and vomiting (53.7%).<\/p>\n<p>Most respondents reported daily or almost daily use (68.3%), and many reported medical marijuana use (61.9%), rather than recreational or combination use.<\/p>\n<p>A total of 87.6% of patients reported improved quality of life with marijuana use, and 59.3% thought marijuana reduced their use of other analgesics. <\/p>\n<p>\u201cMany patients relied on marijuana use to reduce their reliance on opioid pain medications,\u201d Chaudhry said. \u201cThis was an interesting insight demonstrating a more judicious approach in this patient population to avoid potential opioid dependence and addiction.\u201d<\/p>\n<p>Those who used marijuana daily or almost daily reported improved ability to live independently (<i>P<\/i> = 0.0075) and were more likely to be employed (<i>P<\/i> = 0.04). This frequency of use also was linked to patient-reported relief of nausea and vomiting, joint pain and insomnia. <\/p>\n<p>Chaudhry and colleagues noted that use patterns shifted with age and gender.<\/p>\n<p>Younger respondents (<i>P<\/i> = 0.0074) and patients with more recent <a rel=\"noopener noreferrer\" href=\"https:\/\/www.healio.com\/news\/gastroenterology\/20260825\/variation-in-antibody-response-evident-long-before-symptoms-of-ibd-develop\" id=\"rId10\" target=\"_blank\">IBD diagnoses<\/a> (<i>P<\/i> = 0.006) favored recreational use. Medical use was more common among middle-aged adults and patients with a longer duration of disease.<\/p>\n<p>According to the researchers, women were most likely to use oral non-edibles and men were most likely to smoke marijuana (<i>P <\/i>= 0.011).<\/p>\n<h2>Patient knowledge<\/h2>\n<p>Almost all patients (97.9%) indicated they were comfortable informing their physicians about their marijuana use. <\/p>\n<p>\u201cThis may reflect a positive trend in destigmatization by the medical field regarding marijuana, which allows patients to be more transparent about their health practices,\u201d Chaudhry and colleagues wrote.<\/p>\n<p>However, only a quarter (24.5%) of patients reported they had been counseled on how marijuana use may interact with other medications.<\/p>\n<p>\u201cPatients are not aware of the potential for drug interactions between marijuana formulations and their prescription medications,\u201d Chaudhry said. \u201cHence, they may not realize the importance of disclosure of use to their clinical care teams in this context.<\/p>\n<p>\u201cOrganized efforts to educate patients on this front are also lacking from the clinical and pharmaceutical perspective,\u201d she continued.<\/p>\n<p>Respondents demonstrated an understanding of marijuana\u2019s impact on disease course, with 67.6% reporting that it did not contribute to improvement in gut inflammation. <\/p>\n<p>Chaudhry and colleagues acknowledged study limitations, including generalizability due to the single-center design, sample size and <a rel=\"noopener noreferrer\" href=\"https:\/\/www.healio.com\/news\/gastroenterology\/20260901\/mental-healthcare-not-an-optional-addon-for-patients-with-ibd\" id=\"rId11\" target=\"_blank\">psychiatric comorbidity<\/a> burden. Among survey participants, 61.1% reported a formal depression or anxiety diagnosis, and an equal percentage (19.4%) reported having either PTSD or ADD\/ADHD.<\/p>\n<p>Most importantly, Chaudhry added, there is potential for bias, as survey respondents were active marijuana users, likely due to having a beneficial response as opposed to experiencing adverse events or poor response.<\/p>\n<p>\u201cFuture studies, including patients who chose to avoid marijuana use because of poor response or side effects, will provide a broader insight into the patient experience of marijuana use for IBD-related symptoms,\u201d she said. \u201cData are also lacking on effective doses and formulations recommended for symptom control, largely because the regulatory framework governing medical cannabis remains fragmented and underdeveloped.\u201d<\/p>\n<h2>For more information:<\/h2>\n<p>      <b>Naueen A. Chaud<\/b><b>h<\/b><b>ry<\/b><b>, MD,<\/b> can be reached at <a rel=\"noopener noreferrer\" href=\"https:\/\/www.healio.com\/news\/gastroenterology\/20260922\/mailto:gastroenterology@healio.com\" id=\"rId12\" target=\"_blank\">gastroenterology@healio.com<\/a>.<\/p>\n<div class=\"article__content--footer\">\n<div class=\"perspective\">\n    <a id=\"3CD0D62FAE79456EA6417ED505083A87\"\/><br \/>\n    <a id=\"perspective\" name=\"perspective\"\/><\/p>\n<h2 class=\"title\">Perspective<\/h2>\n<p>    <a class=\"back-to-top\" href=\"#top\">Back to Top <i class=\"far fa-arrow-up\"\/> <\/a><\/p>\n<div class=\"perspective-body\">\n<div class=\"img-group\">\n            <img decoding=\"async\" class=\"perspective-img\" src=\"https:\/\/www.healio.com\/~\/media\/slack-news\/gastroenterology\/mugs\/k\/kinnucan_jami.jpg?w=80\" alt=\"Jami A. Kinnucan, MD\"\/>\n        <\/div>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">Despite increasing cannabis legalization and use, particularly among patients with chronic diseases, data in IBD remain limited. This study from the University of Florida IBD clinic provides important insights into cannabis use in a state where access is restricted to medical cannabis.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">Prior studies have shown that cannabis use is often underreported and that patients with IBD who use cannabis may be more likely to discontinue effective medical therapies because of perceived symptom benefit. While limited clinical trials suggest improvement in symptoms, they have not demonstrated objective improvement in intestinal inflammation with currently studied formulations and dosing strategies.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">The clinical implications of this study are that many patients using cannabis perceive meaningful benefits, including symptom relief and improved quality of life. These findings reinforce the importance of routinely screening for cannabinoid use, counseling patients on the distinction between symptom and inflammation control, and encouraging continuation of evidence-based anti-inflammatory therapies.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">Several limitations merit consideration. The study surveyed current users, potentially excluding patients who discontinued cannabis because of lack of benefit or adverse effects, introducing selection bias. In addition, the high prevalence of anxiety, depression and PTSD among users is notable, given the potential for cannabis to worsen some psychiatric comorbidities.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">This work adds to the limited literature on cannabis use in IBD and highlights differences in use patterns by age and disease duration. Future research should focus on the endocannabinoid system and cannabinoid receptor-targeted therapies as adjuncts to established anti-inflammatory treatments, with the goal of achieving objective improvements in inflammation in addition to symptom relief.<\/p>\n<p>&#13;<br \/>\n          <strong> Disclosures: <\/strong> Kinnucan reports no relevant financial disclosures.&#13;\n        <\/p>\n<\/p><\/div>\n<\/p><\/div>\n<div class=\"publisher-logo\">\n    <span>Published by:<\/span><br \/>\n    <img decoding=\"async\" src=\"https:\/\/www.healio.com\/~\/media\/h5\/feature\/news\/publogos\/hgld\/healio_gastro.svg?la=en&amp;h=40&amp;w=152&amp;hash=2C654A538F2E250F5183D42A89FE0EC0\" class=\"logo-img\" height=\"40\" alt=\"Healio Logo - Gastroenterology\" width=\"152\"\/>\n  <\/div>\n<p><!-- Healio AI Widget --><\/p>\n<div class=\"healio-ai-component-inline\" data-no-ads=\"true\" data-module-track-category=\"Healio AI\" data-module-track-action=\"Click\" data-module-track-label=\"Access Healio Ai from component - News_AI Component - In-Content (all devices)\">\n<div class=\"healio-ai-content\">\n    <img decoding=\"async\" src=\"https:\/\/m3.healio.com\/~\/media\/images\/healio-ai\/healio-ai_logo.svg\" alt=\"Healio AI\" class=\"healio-ai-logo\"\/><\/p>\n<p><strong>Ask a clinical question<\/strong> and tap into <strong>Healio AI&#8217;s knowledge<\/strong> base.<\/p>\n<ul>&#13;<\/p>\n<li>PubMed, enrolling\/recruiting trials, guidelines<\/li>\n<p>&#13;<\/p>\n<li>Clinical Guidance, Healio CME, FDA news<\/li>\n<p>&#13;<\/p>\n<li>Healio&#8217;s exclusive daily news coverage of clinical data<\/li>\n<p>&#13;\n    <\/ul>\n<p>    <button class=\"healio-ai-button\" onclick=\"window.location.href=\" https:=\"\">Learn more<\/button>\n  <\/div>\n<\/div>\n<div class=\"email-alert-button-wrapper d-none\" data-component=\"EmailTopicAlert\" data-module=\"Subspecialty Email Topic Alerts Top\" data-manage-email-link=\"\/footer\/account-information\/my-account\/email-subscriptions-and-alerts#emailAlerts\">\n  <hidden data-setting-item=\"d265901d-6d37-49c7-a8f6-c7bf19a02509\"\/><br \/>\n  <hidden data-crm-source=\"Subspecialty Topic Alert\"\/><\/p>\n<div class=\"email-alert-button d-none\" data-topic-button=\"not-subscribed\">\n<p>&#13;<br \/>\n      <span data-module-track-action=\"Email Alerts TOP_Click_Healio News Article\" data-module-track-label=\"Email Alerts TOP_Healio News Article\">&#13;<br \/>\n        <i class=\"fas fa-plus-circle\"\/>&#13;<br \/>\n        Add topic to email alerts&#13;<br \/>\n      <\/span>&#13;\n    <\/p>\n<div class=\"email-alert-inner collapse u72666b614ef0406bbd8736de479e5a93\">\n<div class=\"email-alert-dialogue\">\n<p>&#13;<br \/>\n          Receive an email when new articles are posted on <span data-content=\"topic-title\"\/>&#13;\n        <\/p>\n<div class=\"d-none\" data-sign-up-type=\"unknown\">\n          Please provide your email address to receive an email when new articles are posted on <span data-content=\"topic-title\"\/>.<\/p><\/div>\n<\/p><\/div>\n<p>      <button type=\"button\" class=\"btn btn-primary\" data-loading-text=\"Loading &lt;i class=\" fa=\"\" fa-spinner=\"\" fa-spin=\"\">&#8220;&#13;<br \/>\n              data-action=&#8221;subscribe&#8221;&gt;&#13;<br \/>\n        Subscribe&#13;<br \/>\n      <\/button>\n    <\/div>\n<\/p><\/div>\n<div class=\"d-none\" data-topic-modal=\"failed\">    <strong>We were unable to process your request. Please try again later. If you continue to have this issue please contact <a href=\"https:\/\/www.healio.com\/news\/gastroenterology\/20260922\/mailto:customerservice@slackinc.com\">customerservice@slackinc.com<\/a>.<\/strong>  <\/p>\n<p><button data-dismiss=\"modal\" class=\"btn btn-primary btn-lg btn-block\">Back to Healio<\/button><\/p>\n<\/div>\n<\/div><\/div>\n<\/p><\/div>\n<p><br \/>\n<br \/><a href=\"https:\/\/www.healio.com\/news\/gastroenterology\/20260922\/patients-with-ibd-report-meaningful-benefits-in-symptom-relief-with-marijuana-use\">Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>September 23, 2026 3 min read &#13; &#13; &#13; Add topic to email alerts&#13; &#13; &#13; Receive an email when new articles are posted on &#13; Please provide your email address to receive an email when new articles are posted on . &#8220;&#13; data-action=&#8221;subscribe&#8221;&gt;&#13; Subscribe&#13; We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Key takeaways: Nearly 70% of survey respondents reported daily\/near daily marijuana use for symptom control. Use was tied to patient-reported relief of anxiety, joint pain and nausea\/vomiting, and better quality of life. Patients with inflammatory bowel disease who used marijuana reported symptom relief, improved daily functioning and reduced opioid analgesic use, survey results showed. Prior research indicates some patients with IBD use marijuana to manage disease symptoms or treatment-related adverse events. &#13; &#13;&#13;&#13;&#13;&#13;&#13; &#13; &#13; &#13;&#13; Data derived from Daneshmand A, et al. Med Cannabis Cannabinoids. 2026;doi:10.1159\/000553354.&#13; &#13; Naueen A. Chaudhry \u201cMarijuana use is prevalent for symptom control among patients with IBD and is rising with legalization; however, it is often not discussed in clinic visits,\u201d Naueen A. Chaudhry, MD, assistant professor of gastroenterology at University of Florida, told Healio. \u201cPhysicians managing IBD do not have extensive data on the patient experience and symptom response to marijuana use.\u201d IBD and marijuana use The number of U.S. states in which marijuana use currently is legal \u2014 38 states for medicinal use and 24 for recreational \u2014 continues to expand. Medical marijuana use is legal in Florida, where this study took place, and Crohn\u2019s disease is an approved indication. Chaudhry and colleagues administered a 39-question survey to 108 patients at the University of Florida\u2019s IBD clinic who were diagnosed with CD or ulcerative colitis (51.9% women; 50% aged 26 to 45 years; 79.6% CD) and reported using marijuana. \u201cOur goal was to gain a better understanding of our patients, including their patterns of use, experiences and perceptions of marijuana use in the context of disease-related symptoms,\u201d Chaudhry said. The majority (82.4%) of patients were on pharmacotherapy for IBD, with more than half (56.5%) reporting current biologic use. Participants most often used marijuana for anxiety (60.2%), joint pain (54.6%), and nausea and vomiting (53.7%). Most respondents reported daily or almost daily use (68.3%), and many reported medical marijuana use (61.9%), rather than recreational or combination use. A total of 87.6% of patients reported improved quality of life with marijuana use, and 59.3% thought marijuana reduced their use of other analgesics. \u201cMany patients relied on marijuana use to reduce their reliance on opioid pain medications,\u201d Chaudhry said. \u201cThis was an interesting insight demonstrating a more judicious approach in this patient population to avoid potential opioid dependence and addiction.\u201d Those who used marijuana daily or almost daily reported improved ability to live independently (P = 0.0075) and were more likely to be employed (P = 0.04). This frequency of use also was linked to patient-reported relief of nausea and vomiting, joint pain and insomnia. Chaudhry and colleagues noted that use patterns shifted with age and gender. Younger respondents (P = 0.0074) and patients with more recent IBD diagnoses (P = 0.006) favored recreational use. Medical use was more common among middle-aged adults and patients with a longer duration of disease. According to the researchers, women were most likely to use oral non-edibles and men were most likely to smoke marijuana (P = 0.011). Patient knowledge Almost all patients (97.9%) indicated they were comfortable informing their physicians about their marijuana use. \u201cThis may reflect a positive trend in destigmatization by the medical field regarding marijuana, which allows patients to be more transparent about their health practices,\u201d Chaudhry and colleagues wrote. However, only a quarter (24.5%) of patients reported they had been counseled on how marijuana use may interact with other medications. \u201cPatients are not aware of the potential for drug interactions between marijuana formulations and their prescription medications,\u201d Chaudhry said. \u201cHence, they may not realize the importance of disclosure of use to their clinical care teams in this context. \u201cOrganized efforts to educate patients on this front are also lacking from the clinical and pharmaceutical perspective,\u201d she continued. Respondents demonstrated an understanding of marijuana\u2019s impact on disease course, with 67.6% reporting that it did not contribute to improvement in gut inflammation. Chaudhry and colleagues acknowledged study limitations, including generalizability due to the single-center design, sample size and psychiatric comorbidity burden. Among survey participants, 61.1% reported a formal depression or anxiety diagnosis, and an equal percentage (19.4%) reported having either PTSD or ADD\/ADHD. Most importantly, Chaudhry added, there is potential for bias, as survey respondents were active marijuana users, likely due to having a beneficial response as opposed to experiencing adverse events or poor response. \u201cFuture studies, including patients who chose to avoid marijuana use because of poor response or side effects, will provide a broader insight into the patient experience of marijuana use for IBD-related symptoms,\u201d she said. \u201cData are also lacking on effective doses and formulations recommended for symptom control, largely because the regulatory framework governing medical cannabis remains fragmented and underdeveloped.\u201d For more information: Naueen A. Chaudhry, MD, can be reached at gastroenterology@healio.com. Perspective Back to Top Despite increasing cannabis legalization and use, particularly among patients with chronic diseases, data in IBD remain limited. This study from the University of Florida IBD clinic provides important insights into cannabis use in a state where access is restricted to medical cannabis. Prior studies have shown that cannabis use is often underreported and that patients with IBD who use cannabis may be more likely to discontinue effective medical therapies because of perceived symptom benefit. While limited clinical trials suggest improvement in symptoms, they have not demonstrated objective improvement in intestinal inflammation with currently studied formulations and dosing strategies. The clinical implications of this study are that many patients using cannabis perceive meaningful benefits, including symptom relief and improved quality of life. These findings reinforce the importance of routinely screening for cannabinoid use, counseling patients on the distinction<\/p>\n","protected":false},"author":1,"featured_media":3771,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-3770","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/posts\/3770","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3770"}],"version-history":[{"count":0,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/posts\/3770\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/media\/3771"}],"wp:attachment":[{"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3770"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3770"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3770"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}